Focus On English 7 Answers

[Giraldo Allain]

similar to this old thread, i've got a multiple choice slide set up with about ten choices or so, and resized, etc. to fit into two columns, which is working fine as expected for a sighted user. i ran into an issue though, trying to navigate the choices using JAWS.

upon further inspection back in form view, i see that the choices have been rearranged in a left-to-right, top-to-bottom order (so it's A, F, B, G, etc.). is there any way to manually set the focus order for the answer choices, so screen readers work as intended?

and/or is that something that could be implemented in the future? and/or can automatic formatting into columns be a thing? i've worked around needing more than ten answer choices with a custom question slide, but it would also be nice to support more than ten choices natively. thanks!

Hi Paul! Thanks for reaching out!

Please have a look at this support article on how to customize the Focus Order.

By default, the focus order is left to right and top to bottom. If you still have trouble or can't reorder the items, could you please share a copy of your project with us by submitting a case?

So I suppose something went wrong when I deployed the new module on my first sugar instance. Does anybody knows if there is a custom parameter or something else that defines that the focus drawer is available / disable for a module (and my module is not a BWC but a sidecar module).

The lesson here is a simple one. What is visible is what students are likely to be paying attention to. So, if there is a particular question and answer we want students attending to, it is a sensible idea to remove anything else.

But there was a problem. Her students\u2019 attention was elsewhere. Some were still doing the marking. Others were discussing their answers to other questions with their partner. The explanation the teacher gave to Question 6 was not heard by many of her students.

The easiest way to do this is to reveal just one answer at a time, so students\u2019 attention is firmly focused on the current question. An even more powerful way - although you might need to be an animation whizz - is to ensure only the current question and answer are visible to prevent students\u2019 attention from wandering back to previous questions.

LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads) on and off LinkedIn. Learn more in our Cookie Policy.

"Stolen Focus" by Johan Hari casts a critical eye on the ubiquitous role smartphones play in diluting our capacity to maintain deep, meaningful focus on the tasks that truly matter. This is not merely a matter of personal discipline; it's a systemic issue that touches on the very fabric of how we live and work in a modern society. Understanding the disruptive role of smartphones is vital because it directly impacts our ability to engage deeply with complex problems and devise innovative solutions. In an era where attention is fragmented by incessant notifications and the allure of endless scrolling, recognizing the need to reclaim our focus is the first step towards fostering a culture of sustained productivity and meaningful engagement. This dialogue is essential for anyone committed to personal growth and community impact, as it underscores the importance of intentional action and the transformative power of reclaiming our attention in a distracted world.

This book delves deep into the crisis of attention that plagues our society, particularly spotlighting the colossal impact of smartphone usage on our capability to engage meaningfully with the world around us. As we navigate through the intricate dance of making time for what truly matters, Hari's work provides a crucial understanding that helps us intentionally choose our battles and tasks. It's an essential read for those looking to reclaim the narratives of their lives from the clutches of incessant digital interruptions.

While Hari's analysis is incisive, it parallels issues I remember worrying about while reading Nir Eyal's "Indistractable" - its lack of focus on individuals with less flexibility at home or little power at work. The absence of an intersectional lens in discussing strategies to combat digital distraction somewhat diminishes the power of Hari's structural critiques. Recognizing the diverse challenges faced by individuals across different socio-economic and cultural backgrounds would have added a richer, more inclusive dimension to his already compelling narrative.

I have a form that I only want it to run my code when a pagination page gets focus. Before I just watched for when either the next/previous buttons got clicked or the tab was clicked then check what page had focus. If it was the page I was watching for then I ran the code.

This was done to drastically cut down how often a couple of my lookups were being triggered as part of the data the lookup used is in a table on a previous tab. So each time they added a row or changed a particular field value in that table the lookup I had no need to run just yet would trigger and slow down the form. It was much better to wait until they had entered all of the data in the table and moved to the next tab to run the next lookup(s). These lookup were triggered by manually only copying the unique values entered in the first table, into the next when the tab had focus.

The site is secure.
The ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

A. Cannabis is a plant of the Cannabaceae family and contains more than eighty biologically active chemical compounds. The most commonly known compounds are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Parts of the Cannabis sativa plant have been controlled under the Controlled Substances Act (CSA) since 1970 under the drug class "Marihuana" (commonly referred to as "marijuana") [21 U.S.C. 802(16)]. "Marihuana" is listed in Schedule I of the CSA due to its high potential for abuse, which is attributable in large part to the psychoactive effects of THC, and the absence of a currently accepted medical use of the plant in the United States.

A. At the federal level, the Agriculture Improvement Act of 2018, Pub. L. 115-334, (the 2018 Farm Bill) was signed into law on Dec. 20, 2018. Among other things, this new law changes certain federal authorities relating to the production and marketing of hemp, defined as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." These changes include removing hemp from the CSA, which means that cannabis plants and derivatives that contain no more than 0.3 percent THC on a dry weight basis are no longer controlled substances under federal law.

A. To date, the agency has not approved a marketing application for cannabis for the treatment of any disease or condition. FDA has, however, approved one cannabis-derived and three cannabis-related drug products. These approved products are only available with a prescription from a licensed healthcare provider.

FDA has approved Epidiolex, which contains a purified form of the drug substance CBD for the treatment of seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients 1 years of age and older. It has also approved Epidiolex for the treatment of seizures associated with tuberous sclerosis complex in patients 1 year of age or older. That means FDA has concluded that this particular drug product is safe and effective for its intended use.

The agency also has approved Marinol and Syndros for therapeutic uses in the United States, including for the treatment of anorexia associated with weight loss in AIDS patients. Marinol and Syndros include the active ingredient dronabinol, a synthetic delta-9- tetrahydrocannabinol (THC) which is considered the psychoactive component of cannabis. Another FDA-approved drug, Cesamet, contains the active ingredient nabilone, which has a chemical structure similar to THC and is synthetically derived.

A. No. There are no other FDA-approved drug products that contain CBD. We are aware that some firms are marketing CBD products to treat diseases or for other therapeutic uses , and we have issued several warning letters to such firms. Under the FD&C Act, any product intended to have a therapeutic or medical use, and any product (other than a food) that is intended to affect the structure or function of the body of humans or animals, is a drug. Drugs must generally either receive premarket approval by FDA through the New Drug Application (NDA) process or conform to a "monograph" for a particular drug category, as established by FDA's Over-the-Counter (OTC) Drug Review. CBD was not an ingredient considered under the OTC drug review. An unapproved new drug cannot be distributed or sold in interstate commerce.

FDA continues to be concerned at the proliferation of products asserting to contain CBD that are marketed for therapeutic or medical uses although they have not been approved by FDA. Often such products are sold online and are therefore available throughout the country. Selling unapproved products with unsubstantiated therapeutic claims is not only a violation of the law, but also can put patients at risk, as these products have not been proven to be safe or effective. This deceptive marketing of unproven treatments also raises significant public health concerns, because patients and other consumers may be influenced not to use approved therapies to treat serious and even fatal diseases.

c80f0f1006